MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

ATM-3507

MCE 国际站：ATM-3507

品牌：MedChemExpress (MCE)

货号：HY-100948

CAS 号：1861449⁻⁷0-8

生物活性： ATM-3507 是一种强效的原肌球蛋白抑制剂，在人类黑色素瘤细胞系中 IC50 为 3.83-6.84 µM。

体外研究(In Vitro)：The cell lines differ in their relative expression of Tpm3.1 as well as in the expression of other isoforms. After determing the IC50 concentrations for TR100 and ATM-3507 (CHLA-20: 4.99±0.45 µM, CHP-134: 3.83±0.67 µM, CHLA-90: 6.84±2.37 µM, SK-N-BE(2): 5.00±0.42 µM) in each of the neuroblastoma cell lines, combinations of tropomyosin inhibitors plus Vincristine are tested at levels of each drug alone that kill less than 50% of the neuroblastoma cells. The combinations of both tropomyosin inhibitors plus Vincristine are completely cytotoxic in CHLA-20 cells. All 4 cell lines show some degree of synergy as determined by the Chou–Talalay method. The effect is not limited to the vinca alkaloids as a similar combination efficacy using paclitaxel plus TR100 or ATM-3507[1]. MCE尚未独立确认这些方法的准确性。 仅供参考。

体内研究(In Vivo)：The maximal tolerance dose (MTD) for TR100 and ATM-3507 is 60 and 150 mg/kg, respectively. It is found that a significant inhibition of tumor growth and prolongation of animal survival using either combination compared with each monotherapy. The median survival of mice increased from 18 days for mice treated with ATM-3507 to more than 49 days for mice treated with the combination. It is also found that twice weekly intravenous administration of ATM-3507 also show combination efficacy. The impact of each treatment or the combination on body weight is minimal. Drug levels are measured following the intravenous administration of ATM-3507 at 30 mg/kg in Balb/c mice (n=3 per time point). The mean half-life of ATM-3507 is 5.01 hrs for the terminal elimination phase. The mean AUC0-t in the plasma is 14,548 ng/h/mL. The Cmax of ATM-3507 is 5,758 ng/mL and the the t1/2 is 5.01 h. The observed plasma clearance and volume of distribution at steady state of ATM-3507 is 33.8 mL/min/kg and 7.23 L/kg, respectively[1]. MCE尚未独立确认这些方法的准确性。 仅供参考。

分子量：611.79

Formula：C37H46FN5O2

性状：固体

颜色：White to light yellow

运输条件：美国大陆地区的室温；其他地区可能有所不同。

储存方式： 4°C，避光保存 *溶剂保存：-80°C，6个月；-20°C，1个月（避光保存）

Cell Assay [1]：将4种黑色素瘤细胞系CHLA-20、CHLA-90、SK-N-BE(2)和CHP-134置于37℃、5% CO2的加湿培养箱中培养，培养基中添加100 U/mL青霉素和100 mg/mL链霉素。将细胞以每孔2000-4000个细胞的密度接种于96孔板中，37℃培养过夜后，分别用不同浓度的TR100/ATM-3507（0.1-2.5 µM）单独处理，或用TR100和ATM-3507联合各种化疗药物处理。于第3-5天检测细胞活力。在给药方案优化实验中，第1天加入TR100或长春新碱，第2天加入另一种药物，或者第1天同时加入TR100和长春新碱，并在第5天读取结果。结果以存活细胞百分比表示，并与对照组进行比较。所有细胞活力检测均进行四重复，所示数据代表至少2个独立实验的结果[1]。MCE尚未独立确认这些方法的准确性。仅供参考。

Animal Administration [1]：Mice[1] Female athymic nude mice (age 4-6 weeks) are used. Mice are subcutaneously injected with 5.0×106 CHLA-20 cells in a 150 mL mix of PBS and Matrigel (2:1). ATM-3507 and TR100 are formulated at 15 mg/mL in 30% sulfobutyl-ether-b-cyclodextrin sodium salt (SBECD). Vincristine is dissolved in H2O at 0.125 mg/kg. When the tumors reached volumes of 200-400 mm3, mice are randomized into the study groups. Animals are followed until the animal reached endpoint criteria. Tumor size is measured using digital calipers twice per week and tumor volume is calculated. Mice are also weighed and observed twice per week for signs of endpoint condition. Mice that demonstrate signs of toxicity or reach endpoint criteria are humanely euthanized by CO2 as phyxiation and subjected to cervical dislocation as the secondary method of euthanasia[1]. MCE尚未独立确认这些方法的准确性。 仅供参考。

提供质量检测报告：Data Sheet、SDS、COA、HNMR、LCMS、产品使用指南

产品活性：ATM-3507 是原肌球蛋白 (tropomyosin) 的一个有效抑制剂，其在人类黑色素瘤细胞系中的 IC50 值约为 3.83-6.84 µM。

IC50 & Target：IC50: 3.83-6.84 µM (tropomyosin, in human melanoma celllines)[1].

相关产品：Deruxtecan | Deruxtecan | Oxaliplatin | Cisplatin | Oxaliplatin (Standard) | Nirogacestat | Nirogacestat (Standard) | ATM-3507 (Standard) | Insulin (human) | Insulin solution (human) | Pyropheophorbide-a | PX-478

热门产品线：抑制剂 | 稳定性同位素标记物 | 脂质 | 糖类

Trending products：Inhibitors | Isotope-Labeled Compounds | Lipids | Saccharides

参考文献：
[1]. Currier MA, et al. Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs.Mol Cancer Ther. 2017 Aug;16(8):1555-1565.